CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
Phase 1/2 Recruiting
152 enrolled
Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors
Phase 1/2 Recruiting
70 enrolled
Azacitidine, Venetoclax, and Gilteritinib in Treating Patients With Recurrent/Refractory FLT3-Mutated Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or High-Risk Myelodysplastic Syndrome/Myeloproliferative Neoplasm
Phase 1/2 Recruiting
97 enrolled
Azacitidine and Quizartinib for the Treatment of Myelodysplastic Syndrome or Myelodysplastic/Myeloproliferative Neoplasm With FLT3 or CBL Mutations
Phase 1/2 Recruiting
58 enrolled
A Study of Subcutaneous Blinatumomab Administration in Participants With R/R and MRD+ B-ALL
Phase 1/2 Recruiting
281 enrolled
VITAS: Atezolizumab in Combination With Chemotherapy for Pediatric Relapsed/Refractory Solid Tumors
Phase 1/2 Recruiting
23 enrolled
A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
Phase 1/2 Recruiting
246 enrolled
A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas
Phase 1/2 Recruiting
200 enrolled
TUPELO
Phase 1/2 Recruiting
67 enrolled
A Phase I/II Study of Zotiraciclib for Recurrent Malignant Gliomas With Isocitrate Dehydrogenase 1 or 2 (IDH1 or IDH2) Mutations
Phase 1/2 Recruiting
96 enrolled
Phase 1b/2 Study of Combination 177Lu Girentuximab Plus Cabozantinib and Nivolumab in Treatment naïve Patients With Advanced Clear Cell RCC
Phase 1/2 Recruiting
100 enrolled
TAQE
Phase 1/2 Recruiting
93 enrolled
A Study of Inlexisertib (DCC-3116) in Combination With Anticancer Therapies in Participants With Advanced Malignancies
Phase 1/2 Recruiting
94 enrolled
Pacritinib, a Kinase Inhibitor of CSF1R, IRAK1, JAK2, and FLT3, in Adults and Pediatric Participants 12 Years of Age or Older With Myelodysplastic Syndromes or Myelodysplastic/Myeloproliferative Neoplasms
Phase 1/2 Recruiting
160 enrolled
TranspoCART19
Phase 1/2 Recruiting
27 enrolled
MB-dNPM1-TCR.1 in Relapsed/Refractory AML
Phase 1/2 Recruiting
29 enrolled
A Phase 1/2 Study of KSQ-004EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate Genes Encoding SOCS1 and Regnase-1, in Patients With Select Advanced Solid Tumors
Phase 1/2 Recruiting
141 enrolled
HX009+ IN10018 With or Without Standard Chemotherapy for Advanced Solid Tumours
Phase 1/2 Recruiting
124 enrolled
IOMAB-CAR-T Followed by CAR-T Cell Therapy in R/R DLBCL
Phase 1/2 Recruiting
30 enrolled
Study of Naxitamab and Sacituzumab Govitecan in Patients With Metastatic Triple-negative Breast Cancer (TNBC)
Phase 1/2 Recruiting
31 enrolled
BEACON-1: Study of AVZO-103 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Urothelial Cancer or Other Solid Tumors (AVZO-103-1001)
Phase 1/2 Recruiting
355 enrolled
A Study of TAK-188 in Adults With Advanced or Spreading Solid Tumors
Phase 1/2 Recruiting
223 enrolled
TulmiSTAR-01
Phase 1/2 Recruiting
188 enrolled
A Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA-positive mCRPC
Phase 1/2 Recruiting
123 enrolled
A Study of OTP-01, a Dual Paratopic PD-1/VEGFR2 Antibody, in Patients With Advanced Solid Tumors
Phase 1/2 Recruiting
170 enrolled
UHKT-PTC-TMI-1
Phase 1/2 Recruiting
16 enrolled
ADAPT-BLADDER
Phase 1/2 Recruiting
55 enrolled
A Study of BI-1206 in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors
Phase 1/2 Recruiting
197 enrolled
OPAL
Phase 1/2 Recruiting
144 enrolled
Autologous Stem Cell Transplant Followed by Polatuzumab Vedotin in Patients With B-cell Non-Hodgkin and Hodgkin Lymphoma
Phase 1/2 Recruiting
20 enrolled
CaDAnCe-101
Phase 1/2 Recruiting
614 enrolled
Cabozantinib and Dostarlimab in Recurrent Gynecologic Carcinosarcoma
Phase 1/2 Recruiting
37 enrolled
Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
Phase 1/2 Recruiting
270 enrolled
A Phase I/II Study of Trametinib and Azacitidine for Patients With Newly Diagnosed Juvenile Myelomonocytic Leukemia
Phase 1/2 Recruiting
58 enrolled
A Phase Ib/II Study of an Anti-HER3 Antibody, HMBD-001, With Cetuximab +/- Docetaxel in Advanced Squamous Cell Cancers
Phase 1/2 Recruiting
398 enrolled
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
Phase 1/2 Recruiting
768 enrolled
Green Tea and Quercetin in Combination With Docetaxel Chemotherapy in Castration-resistant Prostate Cancer Patients
Phase 1/2 Recruiting
99 enrolled
A Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies
Phase 1/2 Recruiting
80 enrolled
PEEL-224
Phase 1/2 Recruiting
59 enrolled
A Phase I/II Study of CS2009 in Participants With Advanced Solid Tumors
Phase 1/2 Recruiting
660 enrolled
Study of XNW28012 in Subjects With Advanced Solid Tumors Who Failed Standard Treatments
Phase 1/2 Recruiting
350 enrolled
Phase 1/2: CD45RA Depleted Stem Cell Addback to Prevent Viral or Fungal Infections Post TCRab/CD19 Depleted HSCT
Phase 1/2 Recruiting
100 enrolled
A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer
Phase 1/2 Recruiting
594 enrolled
ASpiRE
Phase 1/2 Recruiting
78 enrolled
Phase I/ II Trial Combining PD-1 Inhibition and Neoadjuvant Proton or Photon Radiation Therapy in Recurrent Head and Neck Squamous Cell Carcinoma
Phase 1/2 Recruiting
40 enrolled
KRAS Neoantigen Nanovaccine as Adjuvant Therapy for Colorectal Cancer/Pancreatic Cancer
Phase 1/2 Recruiting
49 enrolled
A Trial to Study if REGN17372 in Combination With Linvoseltamab is Tolerable for Adult Participants With Relapsed/Refractory Multiple Myeloma
Phase 1/2 Recruiting
150 enrolled
A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors
Phase 1/2 Recruiting
150 enrolled
Nebulized or Inhaled Albuterol for Lymphangioleiomyomatosis
Phase 1/2 Recruiting
100 enrolled
ONC201 in Treating Patients With Relapsed or Refractory Acute Leukemia or High-Risk Myelodysplastic Syndrome
Phase 1/2 Recruiting
120 enrolled